Regulatory and Washington

WASHINGTON — Nearly 1,000 biotech drugs and vaccines for more than 100 diseases are currently under development, according to a new report.

NEW YORK — A judge in New York has blocked a controversial law banning the sale of large-sized sugary drinks, according to published reports.

The New York Times reported that state Supreme Court justice Milton Tingling invalidated the law. Mayor Michael Bloomberg had pushed the rule as a way to promote healthier diets for New Yorkers, but it attracted widespread criticism as intrusive.

ALEXANDRIA, Va. — A report on CBS' "60 Minutes" Sunday explored the aftermath of the nationwide outbreak of fungal meningitis linked to the New England Compounding Center that, according to the Centers for Disease Control and Prevention, has sickened 720 people in 20 states and led to 48 deaths.

AUSTIN, Texas — Legislation proposed in Texas' state legislature would expand the range of vaccines that pharmacists can administer to children.

WASHINGTON — A bill that would expand the pool of patients who qualify for medication therapy management under Medicare was introduced to the House of Representatives Thursday with broad industry support. 

Health policy research group NEHI cites that only 50% of patients take their medications properly as prescribed by their doctor, which costs the nation more than $290 billion annually in avoidable health spending annually. 

A new bill (HB 365) in Florida's state legislature would allow pharmacists to substitute biosimilars for branded biotech drugs, according to published reports. The Sarasota Herald-Tribune reported that the Health Quality Subcommittee of the Florida House of Representatives approved a bill that would allow for substitution while requiring pharmacists to notify prescribing physicians within five days and require the doctor and pharmacist to maintain a record for at least four years. A similar bill (SB 732) is pending in the Florida Senate, according to reports.

WASHINGTON — Republican and Democratic senators have re-introduced legislation that would ban patent settlements between branded and generic drug companies that critics allege violate antitrust laws, according to published reports.

ALEXANDRIA, Va. — The cost of diabetes has increased by more than $70 billion over the past five years, according to new research from the American Diabetes Association.

The ADA announced the release of a report estimating that the total costs of diagnosed diabetes had risen 41%, from 2007's $174 billion to $245 billion in 2012. The report, Economic Costs of Diabetes in the U.S. in 2012, was commissioned by the ADA and addresses increased financial burden, health resources used and lost productivity associated with the disease.